![]() She completed her oncology fellowship training at Fred Hutchinson Cancer Research Center/University of Washington. from Jefferson Medical College and her internal medicine training at the University of Pennsylvania. A board-certified medical oncologist, Dr. ![]() Hunder previously served as medical director at ZymoGenetics, developing therapeutics for oncology and viral hepatitis. Hunder was vice president of clinical development at Seattle Genetics, where she led the brentuximab vedotin clinical program and early phase programs in lymphoma and myeloma. Hunder was vice president, head of clinical development and medical affairs at Acerta Pharma, responsible for the acalabrutinib clinical program and lifecycle strategy. Naomi Hunder, M.D., joined Silverback in 2019, bringing both late-stage and early clinical development experience to the Company. Previously, she held research leadership positions at Novo Nordisk and Trubion Pharmaceuticals, where she oversaw the discovery and preclinical development of therapeutics for oncology and inflammatory conditions. Odegard served as vice president of research at Juno Therapeutics, where she was responsible for discovery, preclinical development, and translational research efforts to advance novel cancer immunotherapies into clinical development. She brings over 15 years of research and drug development experience to the Company. Valerie Odegard, Ph.D., joined Silverback in 2016 and has served as chief scientific officer since 2018. It is awesome to work with them and the entire Silverback team as we create a new generation of much-needed therapies.” “We are at an important growth phase for the company and their ongoing leadership will be critical as we progress SBT6050 through clinical development, as well as advance our robust preclinical pipeline. Odegard and Hunder bring comprehensive drug development expertise to Silverback, as well as a fierce drive for scientific excellence and improving patient outcomes,” said Laura Shawver, Ph.D., chief executive officer of Silverback Therapeutics. Valerie Odegard, Ph.D., has been named president and chief scientific officer, and Naomi Hunder, M.D., has been named chief medical officer. The Company also announced two key executive promotions. Silverback has persisted in understanding how to deliver TLR8 agonists with a good preclinical safety and tolerability profile, and we are excited to lead an investment round that will help Silverback investigate the translatability of these findings to patients with HER2-expressing solid tumors.” “Broad activation of innate immune cells has been difficult to achieve due to systemic toxicities. “Silverback has made impressive progress developing a differentiated approach to immuno-oncology,” said Scott Platshon, principal, EcoR1 Capital. Silverback intends to use the proceeds to support its clinical development of SBT6050, a TLR8 agonist conjugated to a HER2-directed antibody currently in a Phase 1 clinical study for the treatment of HER2-expressing solid tumors, and to advance its robust pipeline of other ImmunoTAC therapeutics. Venture Partners, Nextech Invest Ltd., Hunt Technology Ventures, and Pontifax Venture Capital. Existing investors also participating in the financing included OrbiMed Advisors, U.S. EcoR1 Capital led the round, with participation from new investors including Boxer Capital of Tavistock Group, Fidelity Management & Research Company LLC, Nantahala Capital Management, and RA Capital. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics for the treatment of cancer and other serious diseases, today announced the close of an $85 million Series C financing round. SEATTLE-( BUSINESS WIRE)-Silverback Therapeutics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |